AFFIRM-AHF
A randomised, double-blind placebo controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron deficient patients admitted for acute heart failure (AFFIRM-AHF)
- Stadium
- klaar
- Middel
- ferric carboxymaltose
- Populatie
- Hartfalen
- Fase
- IV
- First Patient In
- 1 juni 2017
- Last Patient In
- 19 juli 2019
- Last Patient Last Visit
- 31 juli 2020
National Lead
dr. P van der Meer
Cardioloog
Studiedirecteur
